No Data
Shapuaisi Pharmaceutical Shareholders Plan to Reduce Stakes; Shares Down 10%
November 22nd A-share investment lightning rod︱Changguang Huaxin: Shareholders Guotou Chuangye Ningbo Fund, Yili Suxin, and Nanjing Daofeng plan to collectively reduce their shareholding by no more than 2.01%.
*Shenzhen Coship Electronics: Termination of the application for reorganization and pre-reorganization to the court.
Express News | Zhejiang Shapuaisi Pharmaceutical: Shareholders plan to reduce their holdings by no more than 5%.
Express News | Zhejiang Shapuaisi Pharmaceutical: Obtained the registration certificate for Tobramycin Eye Drops pharmaceutical.
A-share unusual movement | zhejiang shapuaisi pharmaceutical rose more than 7%, Q3 revenue increased by 23.77% compared to the previous quarter.
Gelonghui on October 31 | zhejiang shapuaisi pharmaceutical (603168.SH) rose more than 7% to 8.5 yuan, with a total market value of 3.2 billion yuan. The company's revenue in the first three quarters was 359.402 million yuan. Among them, the revenue in the third quarter was 122.5498 million yuan, an increase of 23.77% compared to the previous quarter; net income attributable to the parent company was -6.0384 million yuan, narrowing the loss compared to the previous quarter. The company continues to increase its investment in research and development, actively promoting the research and development of new products, and transforming research and development into a driving force for high-quality development. (Gelonghui)
Sharp Ace: Sharp Ace Report for the Third Quarter of 2024
No Data
No Data